Neutrophil and mononuclear leukocyte pathways and upstream regulators revealed by serum proteomics of adult and juvenile dermatomyositis

• Published in: Arthritis research & therapy Vol. 26; no. 1; pp. 196 - 15
• Main Authors: Sparling, A. Clare, Ward, James M., Sarkar, Kakali, Schiffenbauer, Adam, Farhadi, Payam Noroozi, Smith, Michael A., Rahman, Saifur, Zerrouki, Kamelia, Miller, Frederick W., Li, Jian-Liang, Casey, Kerry A., Rider, Lisa G.
• Format: Journal Article
• Language: English
• Published: London BioMed Central 11.11.2024; BioMed Central Ltd; BMC
• Subjects: Adolescent; Adult; Aged; Analysis; Biomarkers; Biomarkers - blood; Blood; Blood Proteins - metabolism; Care and treatment; Child; Dermatomyositis; Dermatomyositis - blood; Dermatomyositis - metabolism; Diagnosis; Disease activity; Female; Gene expression; Genetic aspects; Histology, Pathological; Humans; Juvenile dermatomyositis; Leukocytes, Mononuclear - metabolism; Male; Medical examination; Medicine; Medicine & Public Health; Middle Aged; Monocytes; Neutrophils; Neutrophils - metabolism; Orthopedics; Proteomics - methods; Rheumatology; Signal Transduction - physiology; Von Willebrand factor; Young Adult; United States; Juvenile dermatomyositis; Monocytes; Disease activity; Dermatomyositis; Neutrophils; Biomarkers; Multiplex proteomics
• ISSN: 1478-6362; 1478-6354; 1478-6362
• DOI: 10.1186/s13075-024-03421-7

Objectives Serum protein abundance was assessed in adult and juvenile dermatomyositis (DM and JDM) patients to determine differentially regulated proteins, altered pathways, and candidate disease activity biomarkers. Methods Serum protein expression from 17 active adult DM and JDM patients each was compared to matched, healthy control subjects by a multiplex immunoassay. Pathway analysis and protein clustering of the differentially regulated proteins were examined to assess underlying mechanisms. Candidate disease activity biomarkers were identified by correlating protein expression with disease activity measures. Results Seventy-eight of 172 proteins were differentially expressed in the sera of DM and JDM patients compared to healthy controls. Forty-eight proteins were differentially expressed in DM, 32 proteins in JDM, and 14 proteins in both DM and JDM. Twelve additional differentially expressed proteins were identified after combining the DM and JDM cohorts. C-X-C motif chemokine ligand 10 (CXCL10) was the most strongly upregulated protein in both DM and JDM sera. Other highly upregulated proteins in DM included S100 calcium binding protein A12 (S100A12), CXCL9, and nicotinamide phosphoribosyltransferase (NAMPT), while highly upregulated proteins in JDM included matrix metallopeptidase 3 (MMP3), growth differentiation factor 15 (GDF15), and von Willebrand factor (vWF). Pathway analysis indicated that phosphoinositide 3-kinase (PI3K), p38 mitogen-activated protein kinase (MAPK), and toll-like receptor 7 (TLR7) signaling were activated in DM and JDM. Additional pathways specific to DM or JDM were identified. A protein cluster associated with neutrophils and mononuclear leukocytes and a cluster of interferon-associated proteins were observed in both DM and JDM. Twenty-two proteins in DM and 24 proteins in JDM sera correlated with global, muscle, and/or skin disease activity. Seven proteins correlated with disease activity measures in both DM and JDM sera. IL-1 receptor like 1 (IL1RL1) emerged as a candidate global disease activity biomarker in DM and JDM. Conclusion Coordinate analysis of protein expression in DM and JDM patient sera by a multiplex immunoassay validated previous gene expression studies and identified novel dysregulated proteins, altered signaling pathways, and candidate disease activity biomarkers. These findings may further inform the assessment of DM and JDM patients and aid in the identification of potential therapeutic targets.